Click Therapeutics has filed a notice of an exempt offering of securities to raise $49,999,999.00 in New Funding.

According to filings with the U.S. Securities and Exchange Commission, Click Therapeutics is raising up to $49,999,999.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Click Therapeutics
Click Therapeutics develops prescription digital therapeutics that combine neuroscience, biology, and software to treat diseases with unmet medical needs. Its treatments are designed to be delivered through smartphones and prescribed by physicians, with programs spanning depression, schizophrenia, migraine, breast cancer, and other conditions. The company also develops Software-Enhanced Drugs, which combine digital interventions with pharmacotherapy to provide added clinical benefits compared with medication alone. Click Therapeutics positions itself as a pioneer in patient-centric digital medicine, using proprietary neuromodulatory mechanisms and clinically meaningful interventions across multiple therapeutic areas. Its notable programs include CT-152, also known as Rejoyn, which the company identifies as FDA cleared, CT-155 for negative symptoms of schizophrenia, and CT-132, described as a first-in-class investigational treatment for episodic migraine. The company has also reported collaborations with Boehringer Ingelheim and Ultrahuman to advance its digital therapeutic technologies and commercialization efforts.

To learn more, visit https://www.clicktherapeutics.com/
LinkedIn: https://www.linkedin.com/company/click-therapeutics-inc-

Contact:
David Klein, President and Chief Executive Officer
https://www.linkedin.com/in/davidbklein/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.